News | July 18, 2021
Veeda Clinical Research acquires majority stake in Bioneeds
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has predominantly built a portfolio into veterinary products
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Dr. Reddy's has the rights to distribute 250mn doses in India
The company is working closely with its six manufacturing partners in India
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Essential medicines were made available to more than 150 countries around the world during the pandemic
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Subscribe To Our Newsletter & Stay Updated
